サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784050

原発性胆汁性胆管炎治療薬の世界市場

Primary Biliary Cholangitis Therapeutics

出版日
ページ情報
英文 273 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.26円
原発性胆汁性胆管炎治療薬の世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 273 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

原発性胆汁性胆管炎治療薬の世界市場は2030年までに11億米ドルに達する見込み

2024年に7億7,160万米ドルと推定される原発性胆汁性胆管炎治療薬の世界市場は、分析期間2024-2030年にCAGR 6.7%で成長し、2030年には11億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである一次医薬品は、CAGR 7.8%を記録し、分析期間終了時には8億240万米ドルに達すると予測されます。二次医薬品セグメントの成長率は、分析期間中CAGR 4.3%と推定されます。

米国市場は2億1,020万米ドルと推定、中国はCAGR 10.7％で成長予測

米国の原発性胆汁性胆管炎治療薬市場は、2024年に2億1,020万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを10.7%として、2030年までに2億3,860万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.2%と6.6%と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

原発性胆汁性胆管炎（PBC）治療薬の世界市場- 主要動向と促進要因のまとめ

なぜ原発性胆汁性胆管炎（PBC）治療薬の需要が増加しているのか？

原発性胆汁性胆管炎（PBC）は、胆管の進行性破壊を特徴とする慢性の自己免疫性肝疾患であり、肝障害、線維化、重症例では肝硬変を引き起こします。自己免疫疾患の有病率の増加は、PBCに対する認識の高まりと診断の改善と相まって、効果的な治療薬に対する需要を煽っています。現在の治療オプションは、疾患の進行を遅らせ、疲労やそう痒などの症状を軽減し、肝不全を予防することに主眼が置かれています。ウルソデオキシコール酸（UDCA）は数十年にわたり第一選択薬であったが、オベチコール酸（OCA）などの新薬がUDCAで十分な効果が得られない患者のための第二選択薬として登場しました。さらに、フィブラート系薬剤、免疫調節薬、抗線維化薬などの新規治療標的の研究が勢いを増しており、PBC患者に新たな希望をもたらしています。個別化医療が重視されるようになり、治療方針の決定にバイオマーカーが組み込まれるようになったことで、PBC治療薬の状況はさらに変化しています。ヘルスケアプロバイダーがより効果的で的を絞った治療を模索する中、PBC治療薬市場は大幅な成長を遂げると思われます。

PBC治療薬の成長に影響を与える課題とは？

治療オプションの進歩にもかかわらず、PBC治療薬市場は、その可能性を十分に発揮することを妨げるいくつかの課題に直面しています。主な懸念事項の1つは、OCAのような新薬の価格が高いことで、特に中低所得国では患者へのアクセスが制限される可能性があります。また、本疾患の希少性が大規模臨床試験の実施に難題をもたらし、医薬品開発や規制当局の承認プロセスの遅れにつながっています。さらに、UDCAは多くの患者に有効であるが、PBC患者のかなりの部分は利用可能な治療法に反応しないため、別の治療法が必要となります。PBCはしばしばシェーグレン症候群や関節リウマチなどの他の自己免疫疾患と併存するため、治療プロトコルが複雑になります。さらに、患者の長期治療へのアドヒアランスは、疾患の進行を管理する上で極めて重要であるが、副作用やすぐに症状が緩和されないために治療を中断する患者も多いです。このような課題に対処するためには、研究への継続的な投資、購入しやすい価格への改善、革新的な治療法の開発を加速させるための製薬企業と規制当局との協力体制の強化が必要です。

技術革新と医薬品開発は、PBC治療をどのように前進させているのか？

革新的な薬剤開発とバイオテクノロジーの進歩は、PBC治療薬の状況を一変させ、疾患管理と患者の転帰を改善しています。FXRアゴニストのような胆汁酸受容体アゴニストの出現は、UDCAに反応しない患者の治療選択肢を広げています。抗線維化薬や免疫療法の研究も進んでおり、肝炎や線維化を直接標的とする疾患修飾治療の可能性があります。さらに、バイオマーカー研究の進歩により、早期診断と個別化治療戦略が可能になり、疾患の進行と治療への反応をよりよくモニタリングできるようになっています。AIを活用した創薬プラットフォームは、新規治療ターゲットの同定を加速し、臨床試験や薬事承認に要する時間を短縮しています。遠隔医療や遠隔患者モニタリングなどのデジタルヘルスツールの統合は、患者のアドヒアランスを高め、ヘルスケアプロバイダーにリアルタイムのデータを提供することで、疾病管理をさらに改善しています。このような技術革新が進むにつれて、PBC治療薬はより的を絞った効果的な治療薬となり、患者にとって全体的な標準治療が向上します。

原発性胆汁性胆管炎治療薬市場の成長の原動力は？

原発性胆汁性胆管炎治療薬市場の成長は、自己免疫性肝疾患の有病率の上昇、希少疾患研究への投資の増加、市場開拓の進展など、いくつかの要因によって牽引されています。希少疾病に対する政府の取り組みや資金提供の拡大は、製薬会社による新規PBC治療薬の開発を促し、市場開拓を加速させています。個別化医療やバイオマーカーに基づく治療アプローチの採用が拡大していることも、PBC治療薬の有効性をさらに高めています。さらに、先進的な診断ツールの利用可能性が高まることで、早期発見率が向上し、タイムリーな介入と患者の転帰改善につながります。デジタルヘルスソリューションと患者中心のケアモデルの台頭も市場拡大に寄与しており、より効率的な疾患管理戦略を提供しています。PBC治療薬市場は、この慢性肝疾患に苦しむ患者に新たな改善策を提供することで、認知度と治療選択肢が進化し続ける中、大きな成長が見込まれています。

セグメント

薬剤タイプ（一次治療薬、二次治療薬）、流通チャネル（病院薬局、ドラッグストア・小売薬局、オンライン薬局）

調査対象企業の例

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Calliditas Therapeutics AB
  • CymaBay Therapeutics
  • Escient Pharmaceuticals
  • Gannex Pharma
  • GENFIT
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc（GSK）
  • Glenmark Pharmaceuticals
  • Intercept Pharmaceuticals
  • Ipsen Pharma
  • Lupin Limited
  • Mirum Pharmaceuticals
  • Mylan（now part of Viatris）
  • Nanjing Chia-tai Tianqing Pharmaceutical
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries
  • Zydus Lifesciences Limited

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP32691

Global Primary Biliary Cholangitis Therapeutics Market to Reach US$1.1 Billion by 2030

The global market for Primary Biliary Cholangitis Therapeutics estimated at US$771.6 Million in the year 2024, is expected to reach US$1.1 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2024-2030. Primary Drug, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$802.4 Million by the end of the analysis period. Growth in the Secondary Drug segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$210.2 Million While China is Forecast to Grow at 10.7% CAGR

The Primary Biliary Cholangitis Therapeutics market in the U.S. is estimated at US$210.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$238.6 Million by the year 2030 trailing a CAGR of 10.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.2% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Primary Biliary Cholangitis (PBC) Therapeutics Market - Key Trends & Drivers Summarized

Why Is There an Increasing Demand for Primary Biliary Cholangitis (PBC) Therapeutics?

Primary Biliary Cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive destruction of bile ducts, leading to liver damage, fibrosis, and, in severe cases, cirrhosis. The increasing prevalence of autoimmune diseases, coupled with the rising awareness and improved diagnosis of PBC, has fueled demand for effective therapeutics. Current treatment options primarily focus on slowing disease progression, reducing symptoms such as fatigue and pruritus, and preventing liver failure. Ursodeoxycholic acid (UDCA) has been the first-line therapy for decades, but newer drugs such as obeticholic acid (OCA) have emerged as second-line options for patients who do not respond adequately to UDCA. Additionally, research into novel therapeutic targets, including fibrates, immunomodulators, and anti-fibrotic agents, is gaining momentum, offering new hope for PBC patients. The growing emphasis on personalized medicine and the integration of biomarkers in treatment decisions are further shaping the landscape of PBC therapeutics. As healthcare providers seek more effective and targeted treatments, the PBC therapeutics market is set to witness substantial growth.

What Challenges Are Impacting the Growth of PBC Therapeutics?

Despite advancements in treatment options, the PBC therapeutics market faces several challenges that hinder its full potential. One of the primary concerns is the high cost of newer medications such as OCA, which can limit patient accessibility, particularly in low- and middle-income countries. The rarity of the disease also poses a challenge in conducting large-scale clinical trials, leading to slower drug development and regulatory approval processes. Additionally, while UDCA is effective for many patients, a significant portion of individuals with PBC remain non-responsive to available therapies, necessitating alternative treatment options. Another challenge lies in disease management, as PBC often coexists with other autoimmune conditions such as Sjogren’s syndrome and rheumatoid arthritis, complicating treatment protocols. Furthermore, patient adherence to long-term therapy is crucial for managing disease progression, yet many individuals discontinue treatment due to side effects or lack of immediate symptom relief. Addressing these challenges requires continued investment in research, improved affordability, and greater collaboration between pharmaceutical companies and regulatory bodies to accelerate the development of innovative treatments.

How Are Technological Innovations and Drug Development Advancing PBC Treatment?

Innovative drug development and advancements in biotechnology are transforming the landscape of PBC therapeutics, improving disease management and patient outcomes. The emergence of bile acid receptor agonists, such as FXR agonists, is expanding treatment options for patients who are non-responsive to UDCA. Research into antifibrotic agents and immunotherapies is also progressing, offering potential disease-modifying treatments that target liver inflammation and fibrosis directly. Additionally, advancements in biomarker research are enabling early diagnosis and personalized treatment strategies, allowing for better monitoring of disease progression and response to therapy. AI-driven drug discovery platforms are accelerating the identification of novel therapeutic targets, reducing the time required for clinical trials and regulatory approvals. The integration of digital health tools, such as telemedicine and remote patient monitoring, is further improving disease management by enhancing patient adherence and providing real-time data for healthcare providers. As these innovations continue, PBC therapeutics are becoming more targeted, effective, and accessible, improving the overall standard of care for patients.

What Is Driving the Growth of the Primary Biliary Cholangitis Therapeutics Market?

The growth in the primary biliary cholangitis therapeutics market is driven by several factors, including the rising prevalence of autoimmune liver diseases, increasing investment in rare disease research, and advancements in targeted drug development. The expansion of government initiatives and funding for orphan diseases has encouraged pharmaceutical companies to develop novel PBC therapies, accelerating market growth. The growing adoption of personalized medicine and biomarker-based treatment approaches is further enhancing the effectiveness of PBC therapeutics. Additionally, the increasing availability of advanced diagnostic tools is improving early detection rates, leading to timely interventions and better patient outcomes. The rise of digital health solutions and patient-centric care models is also contributing to market expansion, providing more efficient disease management strategies. As awareness and treatment options continue to evolve, the PBC therapeutics market is expected to witness significant growth, offering new and improved solutions for patients suffering from this chronic liver disease.

SCOPE OF STUDY:

The report analyzes the Primary Biliary Cholangitis Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Primary Drug, Secondary Drug); Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Calliditas Therapeutics AB
  • CymaBay Therapeutics
  • Escient Pharmaceuticals
  • Gannex Pharma
  • GENFIT
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc (GSK)
  • Glenmark Pharmaceuticals
  • Intercept Pharmaceuticals
  • Ipsen Pharma
  • Lupin Limited
  • Mirum Pharmaceuticals
  • Mylan (now part of Viatris)
  • Nanjing Chia-tai Tianqing Pharmaceutical
  • Novartis AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries
  • Zydus Lifesciences Limited

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Primary Biliary Cholangitis Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Autoimmune Liver Disorders Throws the Spotlight on Unmet Needs in PBC Treatment
    • Expansion of Diagnostic Screening Programs Drives Early Detection and Intervention in PBC Cases
    • Growing Acceptance of Ursodeoxycholic Acid (UDCA) as First-Line Therapy Sustains Market Stability in Early-Stage Management
    • Development of Second-Line Therapeutics for UDCA Non-Responders Strengthens Business Case for Advanced Treatment Options
    • Emergence of Farnesoid X Receptor (FXR) Agonists Spurs Innovation in Mechanism-Targeted Drug Development
    • Rising Focus on Bile Acid Modulation Pathways Accelerates Research in Novel Small Molecule Therapies
    • Increased Investment in Rare and Orphan Disease Drug Pipelines Expands Addressable Market for PBC Therapeutics
    • Advancements in Biomarker Discovery Enhance Patient Stratification and Personalized Treatment Strategies
    • Integration of AI and Machine Learning in Drug Discovery Platforms Propels Precision Medicine Approaches in PBC
    • Expansion of Clinical Trials Across North America, Europe, and Asia Drives Globalization of Therapeutic Innovations
    • Strategic Collaborations Between Biotech Firms and Academic Institutions Accelerate Research and Commercialization Efforts
    • Improved Understanding of Immunopathogenesis of PBC Spurs Development of Immunomodulatory Therapies
    • Regulatory Incentives for Orphan Drug Designation Strengthen Pipeline Viability and Accelerate FDA/EMA Approvals
    • Rising Awareness Among Hepatologists and General Practitioners Drives Earlier Diagnosis and Therapeutic Intervention
    • Growth in Patient Advocacy and Rare Disease Networks Propels Demand for Innovative and Accessible Treatment Options
    • Focus on Quality-of-Life Improvements and Fatigue Management Enhances Therapeutic Value Proposition in Chronic PBC Care
    • Emergence of Combination Therapy Paradigms Drives Research in Multi-Targeted Treatment Approaches
    • Availability of Real-World Evidence and Post-Marketing Surveillance Strengthens Confidence in Long-Term Drug Safety
    • Expansion of Specialty Pharmacies and Targeted Distribution Models Sustains Market Access for High-Cost PBC Therapies
    • Challenges in Treatment Adherence and Side Effect Profiles Create Opportunities for Tolerability-Enhanced Formulations
    • Increased Integration of Genomic Data into Clinical Decision-Making Drives Precision Therapeutics in Hepatology
    • Growing Pipeline of Phase II and III Candidates Generates Optimism for Next-Generation PBC Treatment Landscape
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Primary Biliary Cholangitis Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Primary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Primary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Primary Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Secondary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Secondary Drug by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Secondary Drug by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Drug Stores & Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Drug Stores & Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • JAPAN
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • CHINA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • EUROPE
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • FRANCE
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • GERMANY
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • INDIA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030
  • AFRICA
    • Primary Biliary Cholangitis Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Primary Biliary Cholangitis Therapeutics by Drug Type - Primary Drug and Secondary Drug Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Primary Drug and Secondary Drug for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Primary Biliary Cholangitis Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Drug Stores & Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IV. COMPETITION